PHILADELPHIA--(BUSINESS WIRE)--May 8, 2006--Sirtex, a leading developer of targeted and innovative cancer therapies, announces the launch of a clinical trial evaluating the use of SIR-Spheres® microspheres in combination with the oral chemotherapy Xeloda (capecitabine) for patients with advanced metastatic liver cancers. The trial will be conducted in Philadelphia at the Fox Chase Cancer Center, one of the country's leading cancer institutes. Sirtex's SIR-Spheres microspheres are the only FDA-approved radioactive microspheres for the treatment of metastatic liver tumors. Xeloda, manufactured by Roche Pharmaceuticals, is the only FDA-approved oral chemotherapy for metastatic breast cancer, and adjuvant and metastatic colorectal cancer.
